EligibleTrials

A Study of Guselkumab in Participants With Crohn's Disease and Ulcerative Colitis

Recruiting · NCT07606339 · Observational (researchers observe without assigning treatment) · Lead sponsor: Janssen-Cilag Pharma GmbH

View the official record on ClinicalTrials.gov →
Crohn's diseaseUlcerative colitis

What this trial is about

The purpose of this study is to evaluate how long a participant keeps taking guselkumab or continues with their treatment plan without stopping (treatment persistence) in participants with moderate to severe Crohn's disease (CD) or ulcerative colitis (UC) in real-world setting. CD and UC are inflammatory bowel diseases, a group of inflammatory conditions of the colon and small intestine.

Who can take part

Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)

Inclusion criteria

Exclusion criteria

Where it is running

2 locations listed.

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →

Get notified when new trials open

One email when new recruiting trials are added. Unsubscribe anytime.